HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


“Chemophobia” rampant

This article was originally published in The Rose Sheet

Executive Summary

Consumers' perception of chemicals amounts to "chemophobia" - a fear and distrust of chemicals that is not proportionate to their actual risk, according to Dan Gardner, columnist and senior writer for the Ottawa Citizen and author of the book, "The Science of Fear: Why We Fear Things We Shouldn't - And Put Ourselves in Greater Danger." Speaking at a Feb. 25 session of the Personal Care Products Council's annual meeting in Boca Raton, Fla., Gardner cited a study led by risk assessment researcher Dr. Paul Slovic to gauge the public's perception of chemicals in the U.S., UK and Canada. In the study, 75% of participants in each country said they try to avoid chemicals and would not drink water if it contained "even a tiny amount of a carcinogen," roughly 70% that someone exposed to a carcinogen will probably get cancer, and 60% that it is never too expensive to reduce the risk from chemicals, according to Gardner. Chemophobia "drives up the perception of risk," the journalist said. On the other hand, consumer perception of the term "natural" is "as strongly positive as 'chemical' is negative." Gardner suggested that industry adopt a "capitulate-or-fight" strategy - either go green or band together with other consumer product sectors such as the food industry to offer a response "as big and as deep as the problem.

You may also be interested in...

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.



Big Data Offers International Benefits

The HMA-EMA Big Data Task Force has offered recommendations to use data for the benefit of public health.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts